GSK
GSK
740 hedge funds and large institutions have $9.13B invested in GSK in 2016 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 297 increasing their positions, 238 reducing their positions, and 44 closing their positions.
74% more call options, than puts
Call options by funds: $163M | Put options by funds: $94M
25% more repeat investments, than reductions
Existing positions increased: 297 | Existing positions reduced: 238
20% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 44
0% less funds holding
Funds holding: 741 → 740 (-1)
0.14% less ownership
Funds ownership: 3.61% → 3.47% (-0.14%)
4% less capital invested
Capital invested by funds: $9.53B → $9.13B (-$401M)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$61.8M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$34.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.3M |
| 4 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
+$25.6M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$23.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$176M |
| 2 |
JP Morgan Chase
New York
|
-$155M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$78.1M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$55.3M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$33M |
GSK Hedge Fund Activity: Q3 2016 in Review
740 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2016, worth a combined $9.13B — down 4.2% from $9.53B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new GSK positions and 44 closed out — a net gain of 9 holders — while 297 added to existing stakes and 238 trimmed.
The largest buyer was Grantham, Mayo, Van Otterloo & Co (GMO), adding an estimated $61.8M. The largest seller was Macquarie Group, cutting an estimated $176M.
- 740 institutional investors held GSK (GSK) as of Q3 2016, down from 741 in Q2 2016.
- Funds reported $9.13B of GSK stock for Q3 2016, down 4.2% quarter-over-quarter.
- 53 funds opened new GSK positions in Q3 2016 and 44 closed out, a net change of +9 holders.
- The largest GSK buyer in Q3 2016 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $61.8M added.
- The largest GSK seller in Q3 2016 was Macquarie Group, an estimated $176M sold.
Based on aggregated 13F filings for Q3 2016.